<DOC>
	<DOCNO>NCT03036865</DOCNO>
	<brief_summary>Study BOS161721-01 randomize , single center , double-blind , placebo-controlled trial conduct study safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) single ascend intravenous ( IV ) subcutaneous ( SC ) dose BOS161721 placebo healthy adult male female participant .</brief_summary>
	<brief_title>Study Assess Safety , Pharmacokinetics Pharmacodynamics BOS161721 Healthy Subjects</brief_title>
	<detailed_description>Study BOS161721-01 consist 7 single ascend dose ( SAD ) cohort , 8 participant ( 6 active:2 placebo ) , eighth SAD cohort 5 participant ( active ) . Participants randomize 3:1 ratio ( BOS161721 : placebo ) either receive single dose BOS161721 ( 1 , 3 , 10 , 22 , 30 , 60 , 120 , 240 milligram [ mg ] ) placebo . Participants Cohort 1 receive lowest dose , administer IV ( 1 mg ) , follow Cohort 2 , participant receive second low dose , administer SC ( 3 mg ) . BOS161721 placebo also administer SC Cohorts 3 , 4 , 5 , 7 , 8 . Participants Cohort 6 administer IV dose 22 mg ( 5 active ) parallel 60 mg SC-dosed fifth cohort . This dose select generate similar exposure follow 30 mg SC dose . The actual Cohort 6 IV dose may adjust upon available PK data . Participants study 56 week , include Screening Period 28 day , single-dose treatment day ( in-subject treatment period ) , 52-week post-treatment Follow-up Period , require due potential half-life BOS161721 .</detailed_description>
	<criteria>Participant voluntarily agree participate study sign Institutional Review Board ( IRB ) approve informed consent prior perform Screening procedure Participants 18 55 year ( inclusive ) age time Screening , body mass index ( BMI ) 17.5 32 kilogram per meter square ( kg/m^2 ) ( inclusive ) time Screening , weight &gt; 50 kg &lt; 120 kg time Screening , general good health least 8 week prior Screening visit . Good health define individual without know disease ( ) determine responsible physician , base medical evaluation , include medical history , physical examination , laboratory test , image , cardiac monitoring . Women nonchildbearing potential status : Hysterectomy ; Bilateral tubal ligation/tubal occlusion ; Bilateral salpingectomy ; Bilateral oophorectomy ; Postmenopausal define 12 month spontaneous amenorrhea ( In questionable case , blood sample take simultaneous test folliclestimulating hormone ( FSH ) estradiol level , consistent menopausal range . ) Women childbearing potential allow participate agree use least 1 follow contraception method time throughout study participation addition either condom spermicide diaphragm/cervical cap spermicide : Nonhormonal intrauterine device ( IUD ; Paragard®/copper ) Hormonal IUD ( Mirena® ) Nexplanon® implantation progesterone insert skin Males either sterile , agree abstinent Day 1 last study visit , agree use 2 highly effective method contraception : A male condom spermicide ; A sterile sexual partner ; Use female sexual partner IUD spermicide ; female condom spermicide ; contraceptive sponge spermicide ; intravaginal system ; diaphragm spermicide ; cervical cap spermicide ; oral , implantable , transdermal , injectable contraceptive ( ) . Nonsmokers people smoke 5 cigarette per day le 10 pack per year Participants willing able comply study procedure . The criterion inclusion review verified Screening admission . Prior clinical trial experience monoclonal antibody clinically relevant tolerability issue previous administration washout period 60 day 5 halflives ( whichever longer ) occur prior plan first day dose History autoimmune disease ( e.g. , rheumatoid arthritis , Lupus ) History current diagnosis cancer , exception nonmelanoma skin cancer cervical cancer situ treat apparent success curative therapy ( response duration &gt; 5 year ) Asthma , currently treat opinion Principal Investigator likely require additional systemic glucocorticosteroid therapy study , exclusionary . History clinically important drug vaccine allergy anaphylaxis A cluster differentiation 4 ( CD4+ ) lymphocyte count &lt; 500 cell/millimeters cub ( mm^3 ) Screening Positive antikeyhole limpet hemocyanin ( KLH ) antibodies Screening Previous immunization KLH Known allergy shellfish , KLH vaccine , hypersensitivity protein foreign body Levels Immunoglobulin G ( IgG ) Immunoglobulin M ( IgM ) outside reference value deem clinically significant Principal Investigator Screening History sensitivity heparin heparininduced thrombocytopenia Participants cryptosporidium stool sample Screening Abnormal bilirubin alanine aminotransferase ( ALT ) Screening judge Principal Investigator clinically significant Positive urine drug screen Screening Day 1 History alcohol dependence determine positive alcohol serum test Screening Day 1 participant consume 14 ( female participant ) 21 ( male participant ) unit alcohol week ( unit = 1 glass wine [ 125 milliliter ( mL ) /4 ounce ] = 1 measure [ 25 mL/1 ounce ] spirit = 284 mL [ 10 ounce ] beer ) Participants positive test , treat , Hepatitis A , Hepatitis B , Hepatitis C virus , human immunodeficiency virus ( HIV ) , cytomegalovirus ( CMV ) EpsteinBarr virus ( EBV ) . Regarding Hepatitis B , follow would exclude participant study : Participants positive Hepatitis B Surface antigen ( HBsAg ) ; Participants Hepatitis B DNA level &gt; 200 copies/mL ( quantified realtime polymerase chain reaction ) case participant positive Hepatitis B surface antibody ( HBsAb ) negative HBsAg ; Positive Hepatitis B core antibody ( HBcAb ) Current clinical , radiographic , laboratory evidence active tuberculosis ( TB ) A history active TB within last 3 year Screening , even treat Therapy latent TB complete per local country guideline Positive interferon gamma release assay ( IGRA ) TB unless proper treatment document , describe Donation blood ( &gt; 500 mL ) blood product within 2 month ( 56 day ) prior Day 1 Any medically relevant preexist condition could jeopardize safety participant trial Any participant , judgment Principal Investigator , would consider unsuitable clinical trial A shingle infection last 6 month prior Screening Live vaccination use steroid last 2 month prior Screening Use prescription medication ( except oral contraceptive ) overthecounter treatment , include herbal supplement St. John 's Wart ( except multivitamin ) , 2 week prior Screening Participants poor dental health and/or severe foot fungal infection , judge Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Healthy participant</keyword>
	<keyword>BOS161721</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>